Pulse Biosciences (PLSE) has drawn investor attention after recent share price swings, including a gain of 6.4% over the past day and 14.6% over the past week, against mixed longer term returns.

That recent 6.4% 1 day share price gain and 14.6% 7 day share price return come after a 49.6% 90 day share price return and a 59.1% year to date share price return, while the 1 year total shareholder return sits at 25.4% and the 3 year total shareholder return is very large. Momentum has been strong over the medium term even with a weaker 30 day share price patch and a 5 year total shareholder return that is slightly below breakeven.

If this kind of sharp move has you looking beyond a single name, it could be a good time to broaden your search with our 34 healthcare AI stocks as potential next ideas to research.

With shares at US$21.30, a revenue base of just US$0.35m and an annual net loss of US$72.78m, the key question is simple: is Pulse Biosciences undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 3.2% Undervalued

Pulse Biosciences' most followed narrative sees fair value at $22 per share, just above the last close at $21.30. This sets up a finely balanced story between potential and current pricing.

Advancing clinical programs for the nPulse cardiac surgical clamp and nPulse 360 Catheter in atrial fibrillation, including FDA IDE approval, breakthrough designation, and expanding EU feasibility data, creates a path to entry in a high value EP and cardiac surgery market that can expand the company’s addressable revenue base and long term earnings power.

Want to see what sits behind that cardiac opportunity? The narrative focuses on top line expansion, margin reset, and a future earnings multiple that assumes real success. The exact numbers may surprise you.

Result: Fair Value of $22 (UNDERVALUED)

However, this story still depends on trials converting into real procedure volume and on Pulse Biosciences managing high costs against a very small US$0.35m revenue base.

Another Angle on Valuation

Here is the twist. While the popular narrative points to a fair value of $22 per share and labels Pulse Biosciences as slightly undervalued, our cash flow work tells a very different story. The SWS DCF model suggests fair value is closer to $2.57, which would make the current $21.30 share price look expensive. How comfortable are you if those cash flow assumptions prove closer to reality than the growth narrative?

Next Steps

If the mixed messages in this article leave you on the fence, take a moment to check the underlying numbers yourself. Then move quickly to shape your own view with 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If you are serious about building a stronger watchlist, do not stop at a single stock. Use the screener to see what else the market is offering.

• Spot potential mispricings by reviewing 47 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their underlying numbers.
• Build a sturdier core to your portfolio by checking out solid balance sheet and fundamentals stocks screener (41 results) that can help support resilience through different market conditions.
• Get ahead of the crowd by scanning our screener containing 25 high quality undiscovered gems before these names attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.